Proficio Capital Partners LLC Invests $10.88 Million in Illumina, Inc. (NASDAQ:ILMN)

Proficio Capital Partners LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 81,381 shares of the life sciences company's stock, valued at approximately $10,875,000. Proficio Capital Partners LLC owned 0.05% of Illumina at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Golden State Wealth Management LLC bought a new position in Illumina during the fourth quarter worth $32,000. Versant Capital Management Inc boosted its holdings in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after buying an additional 146 shares during the period. Assetmark Inc. grew its stake in Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after buying an additional 296 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock valued at $50,000 after acquiring an additional 141 shares during the period. Finally, V Square Quantitative Management LLC lifted its position in Illumina by 50.6% during the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company's stock worth $52,000 after acquiring an additional 132 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ILMN has been the subject of several research reports. HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target for the company. in a report on Friday, February 28th. Guggenheim reduced their target price on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Canaccord Genuity Group decreased their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a research report on Tuesday, March 11th. Finally, Royal Bank of Canada dropped their price target on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $140.90.

Remove Ads

Illumina Trading Down 0.2 %

Illumina stock traded down $0.20 during trading hours on Wednesday, hitting $84.96. The stock had a trading volume of 2,095,550 shares, compared to its average volume of 2,090,632. The business's 50 day simple moving average is $111.38 and its 200-day simple moving average is $129.20. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66. The stock has a market cap of $13.46 billion, a price-to-earnings ratio of -11.06, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.